216 related articles for article (PubMed ID: 34254464)
21. Review of Palliative
Arays R; Ahmad Z; Howard L; Veselicky K; Kolodney J; SijinWen ; Hogan T
J Nucl Med Technol; 2021 Mar; 49(1):70-74. PubMed ID: 33219158
[TBL] [Abstract][Full Text] [Related]
22. Prognostic biomarkers in the use of radium-223 in patients with metastatic castration-resistent prostate cancer.
Vidal M; Cárdenas-Perilla R; Delgado A; Morón S; Londoño Blair JL; Vega I; Correa Ochoa JJ; Rojas J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(5):310-318. PubMed ID: 37419250
[TBL] [Abstract][Full Text] [Related]
23. Treatment outcomes of radium-223 in patients with metastatic castration-resistant prostate cancer: An experience before National Health Insurance reimbursement in Taiwan.
Yu PH; Wei TT; Chang YH; Chung HJ; Huang EY; Lin TP; Huang WJ
J Chin Med Assoc; 2023 Aug; 86(8):756-761. PubMed ID: 37314313
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study.
Angusti T; DI Stefano RF; Parente A; Bungaro M; Turco F; Samuelly A; Pisano C; Scagliotti GV; DI Maio M; Tucci M; Buttigliero C
Minerva Urol Nephrol; 2022 Dec; 74(6):703-713. PubMed ID: 35147388
[TBL] [Abstract][Full Text] [Related]
25. Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without
Caffo O; Frantellizzi V; Monari F; Galli L; Costa RP; Pinto C; Tucci M; Baldari S; Facchini G; Bortolus R; Alongi F; Alongi P; Donner D; Fanti S; Sbrana A; Morabito A; Masini C; Zichi C; Pignata S; Borsatti E; Salgarello M; Spada M; De Giorgi U; Lo Re G; Cortesi E; De Vincentis G
Cancer Biother Radiopharm; 2021 Jun; 36(5):391-396. PubMed ID: 33769088
[No Abstract] [Full Text] [Related]
26. Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with
Frantellizzi V; Monari F; Mascia M; Costa R; Rubini G; Spanu A; Di Rocco A; Lodi Rizzini E; Cindolo L; Licari M; Lavelli V; Nuvoli S; De Angelis C; Dionisi V; Ferrari C; De Vincentis G
Ann Nucl Med; 2020 Oct; 34(10):772-780. PubMed ID: 32654030
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
Armstrong AJ; Gupta S; Healy P; Kemeny G; Leith B; Zalutsky MR; Spritzer C; Davies C; Rothwell C; Ware K; Somarelli JA; Wood K; Ribar T; Giannakakou P; Zhang J; Gerber D; Anand M; Foo WC; Halabi S; Gregory SG; George DJ
PLoS One; 2019; 14(5):e0216934. PubMed ID: 31136607
[TBL] [Abstract][Full Text] [Related]
29. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.
Etchebehere EC; Milton DR; Araujo JC; Swanston NM; Macapinlac HA; Rohren EM
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):8-20. PubMed ID: 26416392
[TBL] [Abstract][Full Text] [Related]
30. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [
Ahmadzadehfar H; Rahbar K; Baum RP; Seifert R; Kessel K; Bögemann M; Kulkarni HR; Zhang J; Gerke C; Fimmers R; Kratochwil C; Rathke H; Ilhan H; Maffey-Steffan J; Sathekge M; Kabasakal L; Garcia-Perez FO; Kairemo K; Maharaj M; Paez D; Virgolini I
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):113-122. PubMed ID: 32383093
[TBL] [Abstract][Full Text] [Related]
31. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.
Omlin A; Pezaro C; Mukherji D; Mulick Cassidy A; Sandhu S; Bianchini D; Olmos D; Ferraldeschi R; Maier G; Thompson E; Parker C; Attard G; de Bono J
Eur Urol; 2013 Aug; 64(2):300-6. PubMed ID: 23313031
[TBL] [Abstract][Full Text] [Related]
32. The Prognostic Value of Quantitative Bone SPECT/CT Before
Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C
J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369
[TBL] [Abstract][Full Text] [Related]
33. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.
Fosbøl MØ; Petersen PM; Daugaard G; Holm S; Kjaer A; Mortensen J
Ann Nucl Med; 2018 Jan; 32(1):16-21. PubMed ID: 28975586
[TBL] [Abstract][Full Text] [Related]
34. Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223.
Vidal M; Delgado A; Martinez C; Correa JJ; Durango IC
Int Braz J Urol; 2020; 46(4):599-611. PubMed ID: 32213206
[TBL] [Abstract][Full Text] [Related]
35. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
Boegemann M; Khaksar S; Bera G; Birtle A; Dopchie C; Dourthe LM; Everaert E; Hatzinger M; Hercher D; Hilgers W; Matus G; Alvarez LG; Antoni L; Lukac M; Pissart G; Robinson P; Elliott T
BMC Cancer; 2019 Jan; 19(1):60. PubMed ID: 30642291
[TBL] [Abstract][Full Text] [Related]
36. Radium-223 in the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
Peters N; Bambury RM; Power DG; McCarthy L; Lyons C; Kelly P; Jamaluddin MF
Ir Med J; 2022 Feb; 115(2):536. PubMed ID: 35416462
[TBL] [Abstract][Full Text] [Related]
37. A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer.
Miyoshi Y; Tsutsumi S; Yasui M; Kawahara T; Uemura KI; Hayashi N; Nozawa M; Yoshimura K; Uemura H; Uemura H
World J Urol; 2021 Sep; 39(9):3323-3328. PubMed ID: 33644830
[TBL] [Abstract][Full Text] [Related]
38. Bone scan index can be a useful biomarker of survival outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223.
Naito M; Ukai R; Hashimoto K
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1203. PubMed ID: 32721117
[TBL] [Abstract][Full Text] [Related]
39. Radium-223 (Xofigo) with concurrent abiraterone or enzalutamide: predictive biomarkers of improved overall survival in a clinically advanced cohort.
Rathbun JT; Franklin GE
Curr Probl Cancer; 2019 Jun; 43(3):205-212. PubMed ID: 29983206
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]